Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TQH3906 in moderate to severe plaque psoriasis
CTR20243055Phase 2Completed
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQH3906 in plaque psoriasis, sponsored by Nanjing Shunxin Pharmaceutical. Started Aug 2024; status: completed.
02
Drugs
TQH3906
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20243055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243055.